Malaria
From Anvita Health Wiki
Contents |
More Specific Terms
Introduction
- From the Italian mal' aria meaning bad air.
Etiology
-
- transfusion-induced malaria
Epidemiology
- generally occurs between 45 degrees north & 40 degrees south
- Central America ( chloroquine-sensitive)
- South America ( chloroquine-resistant Plasmodium falciparum)
- northern Argentina ( chloroquine-sensitive)
- sub-Saharan Africa
- chloroquine-resistant Plasmodium falciparum
- if malaria is acquire in Africa, likelihood that pathogen is Plasmodium falciparum is 3:1 [4]
- Egypt, Turkey, northern Saudi Arabia ( chloroquine-sensitive)
- middle east ( chloroquine-resistant Plasmodium falciparum)
- India ( chloroquine-resistant Plasmodium falciparum)
- south-east Asia ( chloroquine-resistant Plasmodium falciparum)
- Cambodia (artemisinin-resistant Plasmodium falciparum)
- Polynesia ( chloroquine-resistant Plasmodium falciparum)
- malaria without travel to endemic area
Pathology
- adherence of parasitized erythrocytes to vascular endothelium is a key factor in pathogenesis
- TNF-alpha upregulates expression of adherence receptors ICAM-1 & E-selectin
- platelets kill intraerythrocytic malarial parasites, provide host immunity to malaria [8]
Genetics
- polymorphisms in CD35 may predispose cerebral malaria
- polymorphism in NCR3 is associated with mild suceptibility to malaria
- individuals with sickle cell trait have reduced susceptibility to cerebral malaria
Clinical-manifestations
- prodrome of headache & malaise
- fever/ chills & diaphoresis (abrupt onset)
- fever lasts 1-8 hours
- recurrence of fever
- 48 hours ( Plasmodium vivax & Plasmodium ovale)
- 48 hours or irregular ( Plasmodium falciparum)
- 72 hours ( Plasmodium malariae)
- in early phases of malaria, fever is frequently NOT periodic
- drenching sweats
- edema
- obstructed vessels & hemorrhages
- predicitive of poor outcome
- cerebral malaria - seizures, coma (bad prognosis)
- respiratory distress (bad prognosis)
Laboratory
-
- obtained during or just prior to paroxysms
- Plasmodium falciparum parasitemia
- level of parasitemia of RBC is> 2%
- only ring forms are present
- banana-shaped gametocytes are seen
- RBC of all sizes are affected
- numerous multiply infected RBC are seen
- RBC contain no Schuffner granules
- 24-hour urine urobilinogen: increased urobilinogen
- serology: IFA
- dipstick antigen testing for P. falciparum
- > 100% sensitivity for > 60 parasites/ mL
- 88% specificity
Complications
- death due to cerebral malaria (P. falciparum)
- most deaths in African children < 4 years of age
- multidrug resistance of P. falciparum
Management
- do NOT withhold empiric therapy until peripheral smear is positive
- chloroquine
- oral therapy for uncomplicated malaria
- 10 mg/kg, followed by
- 10 mg/kg at 24 h & 5 mg/kg at 48 h, or
- 5 mg/kg at 12, 14 % 36 hours
- for P. vivax or P. ovale, add primaquine 0.24 mg/kg for 14 days
- parenteral therapy for severe disease
- 15 mg/kg single dose
- add 2nd dose of 10 mg/kg in areas of mefloquine resistance
- atavoquone + proguanil [4]
- artemether + lumefantrine [4]
- oral therapy for uncomplicated malaria
- same as for artesunate
- parenteral therapy for severe disease
- 3.2 mg/kg IM followed by 1.6 mg/kg/day
- artesunate - drug of choice for severe P. falciparum [6]
- oral therapy for uncomplicated malaria
- in combination with mefloquine 25 mg/kg
- 10-12 mg/kg given in divided doses over 3-5 days
- 4 mg/kg for 3 days
- 4 mg/kg, followed by 1.5 mg/kg for 5 days
- used alone
- 10 to 12 mg/kg given in divided doses over 7 days
- 4 mg/kg, followed by
- 2 mg/kg on days 2 & 3 & 1 mg/kf on days 4-7
- parenteral therapy for severe disease [6]
- halofantrine 500 mg every 6 hours
- sulfadoxine/ pyrimethamine
- adults: 1500 mg sulfadoxine/75 mg pyrimethamine single oral dose (3 tablets)
- 20/1 mg/kg children
- self treatment in areas of chloroquine-resistant malaria for travelers taking mefloquine or doxycycline prophylaxis
- oral therapy for uncomplicated malaria
- 10 mg/kg every 8 hours for 7 days, plus tetracycline 4 mg/kg QID, or doxycycline 3 mg/kg QD for 7 days
- parenteral therapy for severe disease
- 20 mg/kg IV infusion over 4 hours, followed by 10 mg/kg over 2-8 h every 8 hours
- addition of clindamycin may shorten parasite clearance time
- parenteral therapy for severe disease, including cerebral malaria
- 10 mg/kg IV infusion over 1-2 hours, followed by 0.02 mg/kg/min with ECG monitoring
- only available parenteral agent in USA
- may add clindamycin
- pentoxifylline may be of benefit, especially for cerebral malaria
- avoid antiplatelet agents [8]
- prophylaxis (see prophylaxis for malaria)
More General Terms
Additional Terms
- artemether
- artesunate
- halofantrine (Halfan)
- malaria without travel to endemic area
- mefloquine (Lariam)
- pentoxifylline (Trental)
- Plasmodium
- prophylaxis for malaria
- quinidine [gluconate (Quinaglute, Quinalan) & sulfate (Quinidex, Quinora)]
Internet Database
OMIM: 609148
References
- DeGowin & DeGowin's Diagnostic Examination, 6th edition, RL DeGowin (ed), McGraw Hill, NY 1994, pg 892
- Clinical Diagnosis & Management by Laboratory Methods, 19th edition, J.B. Henry (ed), W.B. Saunders Co., Philadelphia, PA. 1996, pg 1260-64
- Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 1180-89
- Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, American College of Physicians, Philadelphia 1998, 2006, 2009
- Prescriber's Letter 8(9):54 2001
- Dondorp A, Nosten F, Stepniewska K, Day N, White N; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005 Aug 27-Sep 2;366(9487):717-25. PMID: [1]
- Magill A, Panosian C. Making antimalarial agents available in the United States. N Engl J Med. 2005 Jul 28;353(4):335-7. Epub 2005 Jul 6. No abstract available. PMID: [2] - Centers for Disease Control and Prevention; Filler SJ, MacArthur JR, Parise M, Wirtz R, Eliades MJ, Dasilva A, Steketee R. Locally acquired mosquito-transmitted malaria: a guide for investigations in the United States. MMWR Recomm Rep. 2006 Sep 8;55(RR-13):1-9. Corresponding NGC guideline withdrawn Dec 2011 PMID: [3]
- McMorran BJ et al. Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. Science 2009 Feb 6; 323:797. PMID: [4]
- Dondorp AM et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009 Jul 30; 361:455. <PubMed> PMID: [5] <Internet> [6]
- Malaria: NIH Institute and Center Resources [7]
- Guidelines for Treatment of Malaria in the United States Centers for Disease Control [8]
- CDC Malaria Hotline: (770) 488-7788 Mon-Fri 8 AM-4:30 PM EST (770) 488-7100 after hours, weekends and holidays - National Guideline Clearinghouse
- Guideline for laboratory diagnosis of malaria. British Committee for Standards in Haematology ngc-guideline: [9]
- The prevention of malaria in pregnancy. Royal College of Obstetricians and Gynaecologists (RCOG) ngc-guideline: [10]
- The diagnosis and treatment of malaria in pregnancy. Royal College of Obstetricians and Gynaecologists (RCOG) ngc-guideline: [11]
